Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Melenhorst

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Blood Advances|November 19, 2019
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapyVinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, et al.
Cancer Discovery|October 31, 2015
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyElena Sotillo, David M Barrett, Kathryn L Black, et al.
International Journal of Surgery (London, England)|December 17, 2025
Using a composite end-point and WIN-ratio analysis to evaluate perineal wound healing after abdominoperineal resection for rectal cancer: further insights from the BIOPEX trialsRudolf van den Berg, Gijsbert D Musters, Saskia I Kreisel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2024
Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohortsE G M van Geffen, J M A Langhout, S J A Hazen, et al.
BMC Cancer|September 6, 2022
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)K van den Berg, D P Schaap, E L K Voogt, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Blood Advances|November 19, 2019
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapyVinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, et al.
Cancer Discovery|October 31, 2015
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyElena Sotillo, David M Barrett, Kathryn L Black, et al.
International Journal of Surgery (London, England)|December 17, 2025
Using a composite end-point and WIN-ratio analysis to evaluate perineal wound healing after abdominoperineal resection for rectal cancer: further insights from the BIOPEX trialsRudolf van den Berg, Gijsbert D Musters, Saskia I Kreisel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2024
Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohortsE G M van Geffen, J M A Langhout, S J A Hazen, et al.
BMC Cancer|September 6, 2022
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)K van den Berg, D P Schaap, E L K Voogt, et al.
Pageof 8